AgingResearch.NewsJoin free

Coya Therapeutics

CompanyUnited States

Coya Therapeutics develops one asset, in phase 2 (COYA 302 in amyotrophic lateral sclerosis). Mostly protein or enzyme acting on CD80, CD86 and inflammation; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • COYA 302

    Combines low-dose interleukin-2 and an abatacept biosimilar to enhance regulatory T-cell function and suppress inflammatory immune activation.

    Phase 2, Protein or enzyme, CD80, CD86, amyotrophic lateral sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms8
  • Trials1
  • Similar companies6

Intelligence